Photo-Cured Glycol Chitosan Hydrogel for Ovarian Cancer Drug Delivery
1
Department of Biomedical Sciences, Chonnam National University Medical School, Gwangju 61469, Korea
2
Department of Surgery, Chonnam National University Medical School, Gwangju 61469, Korea
3
Department of Dental Hygiene, College of Health Sciences, Cheongju University, Cheongju 28503, Korea
4
Department of Biomedical Sciences, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea
5
Institute of Cell and Tissue Engineering, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this study.
Mar. Drugs 2019, 17(1), 41; https://doi.org/10.3390/md17010041
Received: 27 December 2018 / Revised: 7 January 2019 / Accepted: 7 January 2019 / Published: 10 January 2019
(This article belongs to the Special Issue Marine Biopolymers and Drug Delivery)
Abstract
In this study, we prepared an injectable drug delivery depot system based on a visible light-cured glycol chitosan (GC) hydrogel containing paclitaxel (PTX)-complexed beta-cyclodextrin (β-CD) (GC/CD/PTX) for ovarian cancer (OC) therapy using a tumor-bearing mouse model. The hydrogel depot system had a 23.8 Pa of storage modulus at 100 rad/s after visible light irradiation for 10 s. In addition, GC was swollen as a function of time. However, GC had no degradation with the time change. Eventually, the swollen GC matrix affected the releases of PTX and CD/PTX. GC/PTX and GC/CD/PTX exhibited a controlled release of PTX for 7 days. In addition, GC/CD/PTX had a rapid PTX release for 7 days due to improved water solubility of PTX through CD/PTX complex. In vitro cell viability tests showed that GC/CD/PTX had a lower cell viability percentage than the free PTX solution and GC/PTX. Additionally, GC/CD/PTX resulted in a superior antitumor effect against OC. Consequently, we suggest that the GC/CD system might have clinical potential for OC therapy by improving the water solubility of PTX, as PTX is included into the cavity of β-CD. View Full-TextKeywords:
injectable drug delivery depot system; visible light-cured glycol chitosan hydrogel; beta-cyclodextrin; paclitaxel; ovarian cancer therapy
▼
Figures
Figure 1
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
Share & Cite This Article
MDPI and ACS Style
Hyun, H.; Park, M.H.; Jo, G.; Kim, S.Y.; Chun, H.J.; Yang, D.H. Photo-Cured Glycol Chitosan Hydrogel for Ovarian Cancer Drug Delivery. Mar. Drugs 2019, 17, 41.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
Related Articles
Article Metrics
Comments
[Return to top]
Mar. Drugs
EISSN 1660-3397
Published by MDPI AG, Basel, Switzerland
RSS
E-Mail Table of Contents Alert